Oncology

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium appoints Ibs Mahmood as Chief Executive Officer

London, UK – November 11, 2025 – Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer

LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...

Prokarium Secures UKRI Grant to Fund Development of Living Cures Platform

LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...

Prokarium Secures UKRI Grant to Fund Development of Living Cures Platform

LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...

Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial

London, UK – February 7, 2024 –  Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...

Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program

London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...

Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program

London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...

Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform

London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...

Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...

Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC

LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...